Patents by Inventor Cyriaque Beley

Cyriaque Beley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9598703
    Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: March 21, 2017
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ DE LAD RECHERCHE MÉDICALE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
    Inventors: Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Michael Kotin, Lina Li
  • Patent number: 9080170
    Abstract: The present invention relates to a method to improve the activity of engineered U7 snRNAs used in the context of RNA-based therapeutics; particularly in exon skipping, exon inclusion, and mRNA eradication strategies. The resulting modified U7 snRNAs are useful for treating neuromuscular diseases, in particular Duchenne neuromuscular dystrophy, myotonic dystrophy DM1 and spinal muscular atrophy.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: July 14, 2015
    Assignee: ASSOCIATION INSTITUT DE MYOLOGIE
    Inventors: Luis Garcia, Denis Furling, Cyriaque Beley, Thomas Voit
  • Publication number: 20140107186
    Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.
    Type: Application
    Filed: March 12, 2012
    Publication date: April 17, 2014
    Applicants: ASSOCIATION INSTITUT DE MYOLOGIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Michael Kotin
  • Publication number: 20130045538
    Abstract: The present invention relates to a method to improve the activity of engineered U7 snRNAs used in the context of RNA-based therapeutics; particularly in exon skipping, exon inclusion, and mRNA eradication strategies. The resulting modified snRNAs are useful for treating neuromuscular diseases, in particular Duchenne neuromuscular dystrophy, myotonic dystrophy DM1 and spinal muscular atrophy.
    Type: Application
    Filed: March 17, 2011
    Publication date: February 21, 2013
    Applicant: ASSOCIATION INSTITUT DE MYOLOGIE
    Inventors: Luis Garcia, Denis Furling, Cyriaque Beley, Thomas Voit